BCL2 and B-cell chronic lymphocytic leukemia: Venetoclax, a Bcl-2 inhibitor (Bcl2i) approved for the treatment of chronic lymphocytic leukemia (CLL) is able to induce primary HCL cell apoptosis in vitro and could be a potential therapy for HCL (13).